Cover Image
Market Research Report
Product code 
1017672

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drugs In Development, 2021

Published: | Global Markets Direct | 61 Pages | Delivery time: 1-2 business days

Price

Back to Top
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drugs In Development, 2021
Published: June 30, 2021
Global Markets Direct
Content info: 61 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Summary:

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Human Cytomegalovirus envelope glycoprotein B plays an important role in host cell entry and cell to cell virus transmission. It is involved in the initial attachment via binding to heparan sulfate together with the gM/gN complex that binds heparin with higher affinity. It interacts with host integrin ITGB1, PDGFRA and EGFR that likely serve as post attachment entry receptors. It participates in the fusion of viral and cellular membranes leading to virus entry into the host cell.

Human Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 10 molecules. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 6 and 1 respectively. Report covers products from therapy areas Infectious Disease, Oncology and Women's Health which include indications Cytomegalovirus (HHV-5) Infections, Chlamydia Infections, Ebolavirus Infections (Ebola Hemorrhagic Fever), Female Contraception, Gonorrhea, Human Immunodeficiency Virus (HIV) Infections (AIDS), Medulloblastoma, Recurrent Glioblastoma Multiforme (GBM), Simplexvirus (HSV) Infections and Trichomonas Vaginitis.

The latest report Human Cytomegalovirus Envelope Glycoprotein B - Drugs In Development, 2021, outlays comprehensive information on the Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Human Cytomegalovirus Envelope Glycoprotein B (gB)
  • The report reviews Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Human Cytomegalovirus Envelope Glycoprotein B (gB)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Human Cytomegalovirus Envelope Glycoprotein B (gB) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Product Code: GMDHC2842TDB

Table of Contents

Table of Contents

  • Introduction
  • Global Markets Direct Report Coverage
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Overview
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Companies Involved in Therapeutics Development
  • AlphaVax Inc
  • Citranvi Biosciences LLC
  • Helocyte Biosciences Inc
  • Merck & Co Inc
  • Stadius Biopharma LLC
  • Trellis Bioscience Inc
  • VBI Vaccines Inc
  • Yaso Therapeutics Inc
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drug Profiles
  • AVX-601 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Bi-specific Monoclonal Antibody to Target CD3 and Glycoprotein B for Cytomegalovirus (HHV-5) Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cytomegalovirus vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cytomegalovirus vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cytomegalovirus vaccine 1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibodies to Inhibit gH and gB for Cytomegalovirus Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PPCM - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TRL-345 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VBI-1501 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VBI-1901 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Dormant Products
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Discontinued Products
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Product Development Milestones
  • Featured News & Press Releases
  • Jun 08, 2021: VBI Vaccines granted FDA fast track designation for VBI-1901 for the treatment of recurrent GBM
  • May 20, 2021: VBI Vaccines to present updated phase 2a tumor response and overall survival data for VBI-1901 in Recurrent GBM at 2021 ASCO Annual Meeting
  • Nov 19, 2020: VBI Vaccines announces positive interim Phase 2a data from VBI-1901 in recurrent GBM
  • Nov 09, 2020: VBI Vaccines announces e-poster presentation at the Society for Neuro-Oncology (SNO) 2020 Virtual Meeting
  • Sep 17, 2020: VBI Vaccines announces biomarker data from VBI-1901 phase 1/2a study in recurrent GBM presented at ESMO Virtual Congress 2020
  • Sep 14, 2020: VBI Vaccines to present additional biomarker data from VBI-1901 phase 1/2a study in recurrent GBM in an E-Poster at ESMO Virtual Congress 2020
  • Jun 22, 2020: VBI Vaccines announces data from VBI-1901 presented at AACR 2020: Partial response observed, promising biomarker strategy identified
  • May 15, 2020: VBI Vaccines announces upcoming poster presentation of Phase 1/2a data of VBI-1901 in Recurrent GBM Patients at AACR Virtual Annual Meeting
  • Mar 03, 2020: VBI Vaccines doses first recurrent GBM patient in trial of VBI-1901
  • Mar 03, 2020: VBI Vaccines provides update on part A of ongoing Phase 1/2a study demonstrating overall survival benefit for VBI-1901 vaccine responders in recurrent GBM patients
  • Nov 22, 2019: VBI Vaccines presents early GBM tumor response and immunologic data from part B of ongoing phase 1/2a study of VBI-1901 at the 2019 SNO Annual Meeting
  • Nov 11, 2019: VBI Vaccines to present initial phase 1/2a part B data of VBI-1901 at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
  • Oct 24, 2019: VBI Vaccines to present new immuno-oncology data at the World Vaccine Congress Europe 2019
  • Sep 11, 2019: VBI to study cancer vaccine with GSK's adjuvant system
  • Jul 29, 2019: VBI Vaccines announces dosing of first recurrent GBM patient in Part B of ongoing phase 1/2a study of VBI-1901
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by AlphaVax Inc, 2021
  • Pipeline by Citranvi Biosciences LLC, 2021
  • Pipeline by Helocyte Biosciences Inc, 2021
  • Pipeline by Merck & Co Inc, 2021
  • Pipeline by Stadius Biopharma LLC, 2021
  • Pipeline by Trellis Bioscience Inc, 2021
  • Pipeline by VBI Vaccines Inc, 2021
  • Pipeline by Yaso Therapeutics Inc, 2021
  • Dormant Projects, 2021
  • Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021